Recent Updates
Recently added Catalysts

PKC412

Phase 1

Acute Myeloid Leukemia | Small molecule | Oncology |Novartis AG|Last Updated: Aug 11, 2017

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedCONTROLLEDBiomarker
Total Trials1
Total Enrollment144
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT00045942PKC412 in Participants With Acute Myeloid Leukemia or With Myelodysplastic Syndrome (CPKC412A2104 Core); and PKC412 in Participants With Acute Myeloid Leukemia or With Myelodysplastic Syndrome With Either Wild Type or Mutated FMS-like Tyrosine Kinase 3 (FLT3) (CPKC412A2104E1 and CPKC412A2104E2)PHASE1 COMPLETED 144 — — Jan 30, 2002Mar 27, 2008Aug 11, 20174 United States
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Number of Participants With Best Clinical Response (Core)
from date of first patient first visit (FPFV), 29-Jan-2002, to date of last participant last visit (LPLV), 04-Sep-2003

Best clinical response was defined as complete response (CR) or partial response (PR), according to NCI definitions for AML and the guidelines for defining responses in MDS.

Percent Decrease in Phospho-FLT3 Compared to Baseline (Core)
days 1, 28
Number of Participants With Overall Clinical Response (E1)
from date of FPFV, 27-Mar-2003, to date of LPLV, 06-Sep-2004

Overall clinical response was defined as CR, PR, minor response (MR) or blast response (BR). CR and PR was defined according to NCI definitions, and MR and BR was defined according to the guidelines for defining hematologic improvement in MDS.

Percent Decrease in Phospho-FLT3 Compared to Baseline (E1)
days 1, 28
Percent Decrease in Phospho-FLT3 Compared to Baseline (E2)
Days 1, 28
Area Under the Plasma Concentration-time Curve From Time Zero to the End of the Dosing Interval Tau (AUCtau) for PKC412 Plasma in the PKC + Itraconazole Combination Arm (E2)
Cycle 1: days 21, 22, 28

Blood samples were collected for pharmacokinetic (PK) analysis.

Observed Maximum Plasma Concentration Following Drug Administration at Steady State (Cmax) for PKC412 in the PKC + Itraconazole Combination Arm (E2)
Cycle 1: days 21, 22, 28

Blood samples were collected for pharmacokinetic (PK) analysis.

Time to Reach the Maximum Concentration After Drug Administration (Tmax) for PKC412 in the PKC412 + Itraconazole Combination Arm (E2)
Cycle 1: days 21, 22, 28

Blood samples were collected for PK analysis.

Area Under the Plasma Concentration-time Curve From Time Zero to the Time of Last Quantifiable Concentration (AUClast) for PKC412 in the PKC412 + Itraconazole Combination Arm (E2)
Cycle 1: days 21, 22, 28

Blood samples were collected for PK analysis.

Terminal Elimination Half-life (T1/2) for PKC412 in the PKC + Itrconazole Combination Arm (E2)
Cycle 1: days 21 and 22

Blood samples were collected for PK analysis.

Area Under the Plasma Concentration-time Curve From Time Zero to the End of the Dosing Interval Tau (AUCtau) for CGP62221 Plasma in the PKC + Itraconazole Combination Arm (E2)
Cycle 1: days 21, 22, 28

Blood samples were collected for pharmacokinetic (PK) analysis.

Observed Maximum Plasma Concentration Following Drug Administration at Steady State (Cmax) for CGP62221 in the PKC + Itraconazole Combination Arm (E2)
Cycle 1: days 21, 22, 28

Blood samples were collected for pharmacokinetic (PK) analysis.

Time to Reach the Maximum Concentration After Drug Administration (Tmax) for CGP62221 in the PKC412 + Itraconazole Combination Arm (E2)
Cycle 1: days 21, 22, 28

Blood samples were collected for PK analysis.

Area Under the Plasma Concentration-time Curve From Time Zero to the Time of Last Quantifiable Concentration (AUClast) for CGP622221 in the PKC412 + Itraconazole Combination Arm (E2)
Cycle 1: days 21, 22, 28

Blood samples were collected for PK analysis.

Terminal Elimination Half-life (T1/2) for CGP62221 in the PKC + Itrconazole Combination Arm (E2)
Cycle 1: day 22,

Blood samples were collected for PK analysis.

Area Under the Plasma Concentration-time Curve From Time Zero to the End of the Dosing Interval Tau (AUCtau) for CGP52421 Plasma in the PKC + Itraconazole Combination Arm (E2)
Cycle 1: days 21, 22, 28

Blood samples were collected for pharmacokinetic (PK) analysis.

Observed Maximum Plasma Concentration Following Drug Administration at Steady State (Cmax) for CGP52421 in the PKC + Itraconazole Combination Arm (E2)
Cycle 1: days 21, 22, 28

Blood samples were collected for pharmacokinetic (PK) analysis.

Time to Reach the Maximum Concentration After Drug Administration (Tmax) for CGP52421 in the PKC412 + Itraconazole Combination Arm (E2)
Cycle 1: days 21, 22, 28

Blood samples were collected for PK analysis.

Area Under the Plasma Concentration-time Curve From Time Zero to the Time of Last Quantifiable Concentration (AUClast) for CGP52421 in the PKC412 + Itraconazole Combination Arm (E2)
Cycle 1: days 21, 22, 28

Blood samples were collected for PK analysis.

Summary of Midostaurin Concentration in the PKC412 Dose Escalation Arms(E2)
Cycle 1: days 1, 2 (24 hr post day 1), 3, 8, 15, 16 (24 hr post day 15), 17, 22; Cycle 2: days 1, 2 (24 hr post day 1), 3, 8, 15

Blood samples were collected for analysis.

Summary of CGP62221 Concentration (E2)
Cycle 1: days 1, 2 (24 hr post day 1), 3, 8, 15, 16 (24 hr post day 15), 17, 22; Cycle 2: days 1, 2 (24 hr post day 1), 3, 8, 15

Blood samples were collected for analysis.

Summary of CGP52421 Concentration (E2)
Cycle 1: days 1, 2 (24 hr post day 1), 3, 8, 15, 16 (24 hr post day 15), 17, 22; Cycle 2: days 1, 2 (24 hr post day 1), 3, 8, 15

Blood samples were collected for analysis.

Secondary Endpoints
Time to Disease Progression (TTP) (Core)
from date of FPFV, 29-Jan-2002, to date of LPLV, 04-Sep-2003
Summary of Midostaurin Plasma Concentration (Core)
Cycle 1: days 1 (24 hour), 3, 8; Cycle 2: day 1,
Summary of CGP62221 Plasma Concentration (Core)
Cycle 1: days 1 (24 hour), 3, 8; Cycle 2: day 1,
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingNONE
ModelSINGLE_GROUP
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
PKC412 (Core)EXPERIMENTALParticipants received 75 mg PKC412 three time daily (tid) orally on a continuous basis until disease progression or the occurrence of unacceptable treatment related toxicity.
FLT3 mutated PKC412 100 mg/day (E1)EXPERIMENTALParticipants received 50 mg PKC412 twice daily (bid) orally on a continuous basis until disease progression or the occurrence of unacceptable treatment related toxicity.
FLT3 mutated PKC412 200 mg/day (E1)EXPERIMENTALParticipants received 100 mg PKC412 twice daily (bid) orally on a continuous basis until disease progression or the occurrence of unacceptable treatment related toxicity.
FLT3 wild type PKC412 100 mg/day (E1)EXPERIMENTALParticipants received 50 mg PKC412 twice daily (bid) orally on a continuous basis until disease progression or the occurrence of unacceptable treatment related toxicity.
FLT3 wild type PKC412 200 mg/day (E1)EXPERIMENTALParticipants received 100 mg PKC412 twice daily (bid) orally on a continuous basis until disease progression or the occurrence of unacceptable treatment related toxicity.
FLT3 mutated PKC412 dose escalationEXPERIMENTALParticipants were treated with PKC412 orally starting at a dose of 100 mg bid. A dose increase up to 300 mg bid was allowed. Participants were treated until time of disease progression, doubling of the bone marrow blast percentage from baseline, or the occurrence of unacceptable toxicity.
FLT3 mutated PKC+Itraconazole (E2)EXPERIMENTALWithin a cycle of 28 days, participants received a loading dose of PKC412 100 mg bid on days 1-2, followed by PKC412 50 mg bid for 3 weeks from days 3-21. On day 22, itraconazole 100 mg bid was added to the treatment regimen. The combinations of PKC412 and Itraconazole continued until disease progression, unacceptable toxicity, or withdrawal of consent.
FLT3 wild type PKC412 dose escalation (E2)EXPERIMENTALParticipants were treated with PKC412 orally starting at a dose of 100 mg bid. A dose increase up to 300 mg bid was allowed. Participants were treated until time of disease progression, doubling of the bone marrow blast percentage from baseline, or the occurrence of unacceptable toxicity.
FLT3 wild type PKC+Itraconazole (E2)EXPERIMENTALWithin a cycle of 28 days, participants received a loading dose of PKC412 100 mg bid on days 1-2, followed by PKC412 50 mg bid for 3 weeks from days 3-21. On day 22, itraconazole 100 mg bid was added to the treatment regimen. The combinations of PKC412 and Itraconazole continued until disease progression, unacceptable toxicity, or withdrawal of consent.
Interventions
NameTypeDescription
ItraconazoleDRUGItraconazole was commercially available.
PKC412DRUGPKC412 was supplied as soft gelatin capsules containing 25 mg PKC412.
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — N/A
SexALL
Healthy VolunteersNo
Study Sites4

Inclusion criteria: 1. Patients: with AML who are not candidates for myelosuppressive chemotherapy or with AML who have relapsed disease or are refractory to standard therapy and not likely to require cytoreductive therapy within one month or with MDS subtypes refractory anemia with excess blas...

Countries:United States
Unlock Eligibility Criteria